Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2066 |
Quizartinib
AC220,奎扎替尼 |
Apoptosis; FLT; Autophagy; Ligands for Target Protein for PROTAC | Angiogenesis; Apoptosis; Autophagy; PROTAC; Tyrosine Kinase/Adaptors |
Quizartinib (AC220) 是一种具有口服活性的高选择性Ⅱ 型 FLT3酪氨酸激酶抑制剂,可诱导细胞凋亡。它抑制 Wt FLT3 和 突变型 FLT3-ITD 自磷酸化,IC50分别为 4.1 nM 和 1.1 nM。它可通过优化的 linker 与 VHL 配体连接,从而形成 PROTAC Flt3 降解剂。 | |||
T39818 |
Desmorpholinyl Quizartinib-PEG2-COOH
Desmorpholinyl Quizartinib-PEG2-COOH |
||
Desmorpholinyl Quizartinib-PEG2-COOH is a compound featuring an FLT-3 ligand and a PEG-based PROTAC linker. It is employed in the synthesis of PROTAC FLT-3 degrader 1, which serves as a degrader for the FLT-3 internal tandem duplication (ITD) through PROTAC technology. The degrader exhibits an IC50 of 0.6 nM. | |||
T71400 |
Quizartinib HCl
|
||
Quizartinib, also know as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell pro... | |||
T71399 |
Plogosertib
CYC140 |
PLK | Cell Cycle/Checkpoint |
Plogosertib (CYC140) 是一种具有口服活性、选择性、高效性和 ATP 竞争性的 PLK1 抑制剂 ,IC50 值为 3 nM。Plogosertib 具有抗增殖和抗癌活性,可用于研究实体瘤和血液肿瘤。 |